Meeting
2023 ASCO Annual Meeting
Elucidating the genomic and transcriptomic landscape of L858R vs ex19del EGFR-mutated NSCLC.
Authors
Stephanie Pei Li Saw
National Cancer Centre Singapore, Singapore, Singapore
Stephanie Pei Li Saw , Mengyuan Pang , Jia Chi Yeo , Jacob Alvarez , Ngak Leng Sim , Win Pin Ng , Gillianne Lai , Aaron C. Tan , Amit Jain , Wan Ling Tan , Ravindran Kanesvaran , Quan Sing Ng , Darren Wan-Teck Lim , Mei-Kim Ang , Tony Kiat Hon Lim , Boon-Hean Ong , Kevin Lee Min Chua , Daniel Shao-Weng Tan , Anders Skanderup
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8530)
DOI
10.1200/JCO.2023.41.16_suppl.8530
Abstract #
8530
Poster Bd #
157
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of alterations in multiple tumor suppressor genes with poor outcomes in patients with EGFR-mutant lung cancer.
First Author: Paul Stockhammer
Poster
2022 ASCO Annual Meeting
Co-occurring gene alterations associated with efficacy of osimertinib in EGFR-mutated lung cancer: Based on a large-scale genomic screening project (LC-SCRUM-Asia).
First Author: Yuji Shibata
Poster
2021 ASCO Annual Meeting
Genomic and immunologic characterization of large-cell neuroendocrine carcinoma of the lung.
First Author: Chul Kim
Poster
2019 ASCO Annual Meeting
Clonal evolution and osimertinib resistance mechanisms identified by whole exome and transcriptome sequencing in EGFR mutant NSCLC.
First Author: Nitin Roper